Arrowhead Pharmaceuticals, Inc. Stock price

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
28.6 USD -0.35% Intraday chart for Arrowhead Pharmaceuticals, Inc. +1.31% -6.54%
Sales 2024 * 126M Sales 2025 * 181M Capitalization 3.54B
Net income 2024 * -313M Net income 2025 * -300M EV / Sales 2024 * 24.8 x
Net cash position 2024 * 426M Net cash position 2025 * 313M EV / Sales 2025 * 17.9 x
P/E ratio 2024 *
-10.4 x
P/E ratio 2025 *
-11.3 x
Employees 525
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.5%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Arrowhead Pharmaceuticals, Inc.

1 day-0.35%
1 week+1.31%
Current month-10.90%
1 month-15.88%
3 months-7.74%
6 months+6.20%
Current year-6.54%
More quotes
1 week
27.31
Extreme 27.31
29.08
1 month
27.00
Extreme 27
36.72
Current year
27.00
Extreme 27
39.83
1 year
20.67
Extreme 20.67
42.48
3 years
20.67
Extreme 20.67
93.66
5 years
17.30
Extreme 17.3
93.66
10 years
1.20
Extreme 1.2
93.66
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 07-11-30
Director of Finance/CFO 57 08-12-31
Chief Tech/Sci/R&D Officer - 22-07-31
Members of the board TitleAgeSince
Chairman 71 10-11-22
Director/Board Member 64 11-12-18
Director/Board Member 79 20-08-31
More insiders
Date Price Change Volume
24-03-28 28.6 -0.35% 589,030
24-03-27 28.7 +3.09% 537,605
24-03-26 27.84 -0.18% 710,015
24-03-25 27.89 +2.50% 517,415
24-03-22 27.21 -3.61% 712,149

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
28.6 USD
Average target price
55.15 USD
Spread / Average Target
+92.85%
Consensus
  1. Stock
  2. Equities
  3. Stock Arrowhead Pharmaceuticals, Inc. - Nasdaq